NASDAQ · MDXH
MDxHealth S.A.
$0.18-$0.01 (-5.63%)
MDxHealth S.A.’s quoted price sits in the lower half of its reported 52-week range, 96.36% below the high.
Loading market information…
OTC · TBPMF · USD
Stock price, earnings
Quote as of Sep 15, 2023, 05:28 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tetra Bio-Pharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tetra Bio-Pharma Inc. (TBPMF) is a biopharmaceutical company dedicated to discovering and advancing cannabinoid-based medications. Its research and development efforts span crucial medical fields, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features several key drug candidates: PLENITUDE is being developed to address cancer-related pain in advanced-stage patients. REBORN is designed to manage breakthrough cancer pain. Reduvo targets chemotherapy-induced nausea and vomiting. ARDS-003 aims to treat sepsis and prevent acute respiratory distress syndrome. SERENITY is focused on treating cancer cachexia. Further candidates include PPP003 for painful dry eye and uveitis, and HCC011, intended for hepatocellular carcinoma (liver cancer). In a strategic collaboration, Tetra Bio-Pharma has partnered with Cellvera Global Holdings LLC for the joint development of ARDS-003. This endeavor will see ARDS-003 formulated as a combination therapy alongside Qifenda 400MG (Favipiravir), which is a commercially available and widely recognized broad-spectrum antiviral drug. The company's operations are headquartered in Orléans, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.18-$0.01 (-5.63%)
MDxHealth S.A.’s quoted price sits in the lower half of its reported 52-week range, 96.36% below the high.
$0.01-$0.00 (-14.89%)
Bionomics Limited’s quoted price sits in the lower half of its reported 52-week range, 89.09% below the high.
$0.04$0.00 (0.0%)
Top Strike Resources Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.50+$0.48 (+2,269.67%)
HealthBeacon plc’s quoted price sits in the lower half of its reported 52-week range, 82.76% below the high.
$0.09-$0.01 (-7.0%)
Immune Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.85% below the high.
$300.00-$100.50 (-25.09%)
Forward Pharma A/S’s quoted price sits in the lower half of its reported 52-week range, 66.02% below the high.
$0.03+$0.03 (0.0%)
Carebook Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.51% below the high.
$1.99+$0.01 (+0.3%)
Polydex Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 1.19% below the high.
